Novo Nordisk to create the world's first all-diabetes professional cycling team

Novo NordiskNovo Nordisk announced a unique partnership to form Team Novo Nordisk, a global sports team with more than 100 cyclists, triathletes and runners who all have diabetes, spearheaded by the world's first all-diabetes pro-cycling team.

Team Novo Nordisk will use life experiences and competitiveness to motivate people affected by diabetes. Throughout 2013, these athletes will compete in more than 500 sporting competitions around the world. The men's pro-cycling team will compete in races such as the USA Pro Cycling Challenge, the Tour of Britain and the Paris-Tours, with the ultimate goal of joining the Tour de France.

"As part of our long-standing Changing Diabetes® programme, this partnership provides a tremendous opportunity to raise awareness, and educate, empower and inspire people with diabetes," says Jakob Riis, senior vice president, Global Marketing and Global Medical Affairs, Novo Nordisk. "This is yet another way Novo Nordisk is striving to create more opportunities to live well with diabetes."

Phil Southerland founded what was known as 'Team Type 1' in 2005 and included riders and athletes with and without diabetes until this year. The new Team Novo Nordisk will only comprise of athletes who have diabetes and will continue to grow the team mission "to instil hope and inspiration for people around the world affected by diabetes."

"As Team Novo Nordisk we want to show the world what is possible with great diabetes control. Between us, Team Novo Nordisk has over 1,000 diagnosed years of diabetes with no complications and we stand for what life with diabetes can be like," Southerland says. "Exercise is that billion dollar drug that nobody ever gets prescribed, and in my experience is the best of them all. With appropriate diet, exercise, treatment and technology, anyone with diabetes can achieve their dreams."

About Diabetes
Today, 371 million people are living with diabetes.(1) Changing Diabetes® is Novo Nordisk's global commitment to improve conditions for the millions of people who live with diabetes around the world today, and those who are at risk of developing diabetes tomorrow. It is a global advocacy and partner platform which advocates for the prevention and early detection of diabetes, as well as improved treatment, care and health outcomes.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

1. International Diabetes Federation. IDF Diabetes Atlas, 5th Edition, 2012 Update. Brussels, Belgium: International Diabetes Federation.

Most Popular Now

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

MedImmune and Sanofi Pasteur form alliance to deve…

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have announced an agreement to develop a...

Read more

FDA approves once-daily Qtern (dapagliflozin and s…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of typ...

Read more

Cooking at home tonight? It's likely cheaper and h…

Researchers from the University of Washington School of Public Health have been peeking into kitchens - via interviews - for years now. They've just published results sho...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]